Roche, UK’s DxS Sign Distribution Pact For Cancer Gene Test
And studies into lung cancer have shown that some patients carry mutations in the epidermal growth factor receptor gene which can affect how they respond to tyrosine kinase inhibitor therapies, like AstraZeneca PLC’s (AZN.LN) Iressa.
This entry was posted on Monday, June 2nd, 2008 at 12:13 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.